IntroductionRenal cell carcinoma (RCC) is one of the most usual kidney's tumors. The
improvement of non-invasive biomarkers will make it feasible to investigate whose have …

Circulating tumor cells (CTCs) have a potential role as the missing renal cell carcinoma
(RCC) biomarker. However, the available evidence is limited, and detection methods lack …

Renal cell carcinoma (RCC) is the most common tumor of the kidney. After diagnosis, 20–
30% of patients will relapse, with a high probability of death from cancer-related causes. The …

Methods A total of 34 patients with advanced RCC (stage III or IV) were prospectively
enrolled, and 104 peripheral blood samples were analyzed for the presence of CTCs at …

The presence of circulating tumor cells (CTCs) in patients with solid tumors is associated
with poor prognosis. However, there are limited data concerning the detection of CTCs in …

Abstract Approximately 30-40% of primary and localized renal cell carcinoma (RCC) will
eventually become metastatic disease. Therefore, the detection and molecular …

Simple Summary Renal cell carcinoma (RCC) is the most common form of kidney cancer,
characterized by silent progression at early stages, heterogeneous behavior and resistance …

Renal cell carcinoma is a highly malignant cancer that would benefit from non-invasive
innovative markers providing early diagnosis and recurrence detection. Circulating tumor …

Background: Recent evidence supports the hypothesis that the CellSearch assay, used in
the enumeration of circulating tumor cells (CTCs), may underestimate the number of CTCs …

Abstract Background and Objectives Circulating tumor cells (CTCs) as a noninvasive
detection technology have become a research hotspot in the field of precision medicine …